Topic: Coronavirus

Latest content

Relaxing patent rights in a pandemic is a win for innovators and the public

The long read: Womble Bond Dickinson’s Ben Bourke takes a deep dive into how life science companies have handled their IP portfolios over the covid-19 pandemic – in particular Moderna Therapeutics’ pledge not to enforce patents relating to its vaccine – and examines how such adjustments can prepare the ground for future inventions

07 April 2021

Europe is seeing a boom in pharma and biotech patenting

A surge in life sciences applications offset a disappointing performance in other areas, the latest EPO statistics suggest

25 March 2021

We worked at triple speed on vaccine patent strategy to help the world, says BioNTech IP chief

“You could go through a practice of 30 years, never experiencing what we have just been through in a year,” says Julie Anne Gillespie in exclusive interview alongside colleague James Ryan

16 March 2021

Covid-19 patent landscape confusion is a big concern for life sciences organisations

Providing new insights into recent filings, but patent landscape uncertainties may pose dangers in the wake of the pandemic

09 March 2021

UK court clarifies when patents can be used without owner authorisation for “the service of the crown”

Concerns that rarely deployed Crown Use might become more commonplace have been significantly alleviated after appeals judges deliver ruling in IPCom v Vodafone

03 March 2021

Negotiating patent licensing agreements during a pandemic

Co-published - Although some major deals in the semiconductor space have been concluded over the last year, respondents to a survey on virtual negotiations see major difficulties in online discussions

02 March 2021

Japan records 6% decline in patent filings for 2020

Preliminary figures also show a drop in PCT filings naming JPO as the receiving office

01 March 2021

No, IP rights are not the barrier to covid-19 vaccine supplies

Continued criticism of biopharma patent owners fails to acknowledge that manufacturing and supply complexities are the real obstacles to mass inoculation around the world

06 February 2021

The biggest life sciences IP stories of 2020

Although the year was dominated by the response to covid-19, there were other major developments as well

30 December 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.

22 December 2020

Unlock unlimited access to all IAM content